J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.BO)
INR 1577.15
(-2.06%)
INR 1577.15
(-2.06%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.82 Billion INR | -43.07% |
| 2022 | 4.95 Billion INR | 25059.45% |
| 2021 | -19.85 Million INR | -112.18% |
| 2020 | 163.02 Million INR | 144.49% |
| 2019 | 66.67 Million INR | 169.46% |
| 2018 | -95.99 Million INR | -811.04% |
| 2017 | 13.5 Million INR | -96.63% |
| 2016 | 401.15 Million INR | -77.84% |
| 2015 | 1.81 Billion INR | 63.66% |
| 2014 | 1.1 Billion INR | 51.2% |
| 2013 | 731.53 Million INR | 213.02% |
| 2012 | 233.7 Million INR | 485.48% |
| 2011 | 39.91 Million INR | -79.0% |
| 2010 | 190.03 Million INR | -67.75% |
| 2009 | 589.17 Million INR | -56.33% |
| 2008 | 1.34 Billion INR | -25.62% |
| 2007 | 1.81 Billion INR | 17.8% |
| 2006 | 1.53 Billion INR | 83.26% |
| 2005 | 840.25 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 2.82 Billion INR | -28.27% |
| 2023 Q2 | 3.58 Billion INR | 33.26% |
| 2023 Q3 | 3.93 Billion INR | 9.63% |
| 2023 FY | 2.82 Billion INR | -43.07% |
| 2023 Q1 | 2.69 Billion INR | -45.67% |
| 2022 FY | 4.95 Billion INR | 25059.45% |
| 2022 Q1 | 566.5 Million INR | 2953.49% |
| 2022 Q3 | 1.96 Billion INR | -32.12% |
| 2022 Q4 | 4.95 Billion INR | 151.76% |
| 2022 Q2 | 2.89 Billion INR | 411.86% |
| 2021 FY | -19.85 Million INR | -112.18% |
| 2021 Q1 | 6.93 Billion INR | 4154.96% |
| 2021 Q4 | -19.85 Million INR | -100.26% |
| 2021 Q3 | 7.67 Billion INR | 3713.01% |
| 2021 Q2 | 201.23 Million INR | -97.1% |
| 2020 Q3 | 4.95 Billion INR | 13139.94% |
| 2020 FY | 163.02 Million INR | 144.49% |
| 2020 Q4 | 163.02 Million INR | -96.71% |
| 2020 Q2 | -37.99 Million INR | -101.04% |
| 2020 Q1 | 3.66 Billion INR | 5395.52% |
| 2019 Q1 | 3.97 Billion INR | 4236.08% |
| 2019 FY | 66.67 Million INR | 169.46% |
| 2019 Q2 | 132.23 Million INR | -96.67% |
| 2019 Q4 | 66.67 Million INR | -98.84% |
| 2019 Q3 | 5.73 Billion INR | 4237.63% |
| 2018 Q1 | 4.12 Billion INR | 0.0% |
| 2018 Q4 | -95.99 Million INR | 0.0% |
| 2018 FY | -95.99 Million INR | -811.04% |
| 2017 FY | 13.5 Million INR | -96.63% |
| 2016 FY | 401.15 Million INR | -77.84% |
| 2016 Q4 | 354.73 Million INR | 0.0% |
| 2015 FY | 1.81 Billion INR | 63.66% |
| 2015 Q4 | 1.8 Billion INR | 0.0% |
| 2014 FY | 1.1 Billion INR | 51.2% |
| 2013 FY | 731.53 Million INR | 213.02% |
| 2012 FY | 233.7 Million INR | 485.48% |
| 2011 FY | 39.91 Million INR | -79.0% |
| 2010 FY | 190.03 Million INR | -67.75% |
| 2009 FY | 589.17 Million INR | -56.33% |
| 2008 FY | 1.34 Billion INR | -25.62% |
| 2007 FY | 1.81 Billion INR | 17.8% |
| 2006 FY | 1.53 Billion INR | 83.26% |
| 2005 FY | 840.25 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alkem Laboratories Limited | -1.6 Billion INR | 275.295% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 1233.959% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 27.023% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 156.284% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 23.613% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 15394.373% |
| Eris Lifesciences Limited | 13.8 Billion INR | 79.566% |
| FDC Limited | -57.75 Million INR | 4985.026% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 199.245% |
| Ipca Laboratories Limited | 11.41 Billion INR | 75.286% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 302.974% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -45.955% |
| Laurus Labs Limited | 24.38 Billion INR | 88.43% |
| Lupin Limited | 17.19 Billion INR | 83.59% |
| Medicamen Biotech Limited | 160.31 Million INR | -1659.774% |
| Medico Remedies Limited | 78.67 Million INR | -3485.8% |
| Megasoft Limited | 1.28 Billion INR | -119.454% |
| NATCO Pharma Limited | -5.81 Billion INR | 148.499% |
| Piramal Pharma Limited | 42.27 Billion INR | 93.327% |
| Sigachi Industries Limited | 859.94 Million INR | -228.066% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 71.87% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 103.893% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -1845.977% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -6005.04% |
| Themis Medicare Limited | 764.96 Million INR | -268.803% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 91.137% |
| Valiant Laboratories Limited | -295.03 Million INR | 1056.235% |
| Wanbury Limited | 1.1 Billion INR | -155.11% |
| Windlas Biotech Limited | -273.04 Million INR | 1133.255% |
| ZIM Laboratories Limited | 983.6 Million INR | -186.823% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 27.883% |
| Ajanta Pharma Limited | -954.9 Million INR | 395.445% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 167.931% |
| Achyut Healthcare Limited | -3.74 Million INR | 75412.333% |
| Lasa Supergenerics Limited | 205.79 Million INR | -1270.852% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 399.554% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -8.013% |
| Alpa Laboratories Limited | 35.36 Million INR | -7877.83% |
| Gufic Biosciences Limited | 3.19 Billion INR | 11.681% |
| Ind-Swift Limited | 9.5 Billion INR | 70.33% |
| Indoco Remedies Limited | 6.47 Billion INR | 56.438% |
| Hester Biosciences Limited | 2.29 Billion INR | -23.157% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 343.679% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 14.482% |
| RPG Life Sciences Limited | -364.7 Million INR | 873.567% |
| Mankind Pharma Limited | -9.9 Billion INR | 128.474% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 165.835% |
| Unichem Laboratories Limited | 931.91 Million INR | -202.731% |
| Bal Pharma Limited | 1.26 Billion INR | -123.274% |
| Strides Pharma Science Limited | 23.25 Billion INR | 87.869% |
| Venus Remedies Limited | -267.7 Million INR | 1153.866% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 89.579% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 78.152% |
| Divi's Laboratories Limited | -39.77 Billion INR | 107.094% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 54.181% |
| Shilpa Medicare Limited | 9.06 Billion INR | 68.894% |
| Aarti Drugs Limited | 5.54 Billion INR | 49.153% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 356.17% |
| Suven Life Sciences Limited | -1.63 Billion INR | 272.794% |
| Hikal Limited | 7.96 Billion INR | 64.589% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 220.153% |
| Sequent Scientific Limited | 4.17 Billion INR | 32.485% |
| Novartis India Limited | -5.89 Billion INR | 147.889% |
| Granules India Limited | 9.28 Billion INR | 69.621% |
| Wockhardt Limited | 18.27 Billion INR | 84.558% |
| Brooks Laboratories Limited | 49.48 Million INR | -5601.122% |
| Neuland Laboratories Limited | -214.05 Million INR | 1417.961% |
| Morepen Laboratories Limited | -231.17 Million INR | 1320.379% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -2250.236% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -189.113% |